多囊卵巢综合征患者血清白介素-18/转化生长因子-β水平与内分泌指标的相关性

Correlation between serum IL-18/TGF-βlevels and endocrine indexes in patients with polycystic ovary syndrome

目的探讨多囊卵巢综合征(PCOS)患者血清白介素-18(IL-18)/转化生长因子-β(TGF-β)与内分泌代谢失调的关系。方法选取2018年4月至2019年11月新疆医科大学第二附属医院收治的70例PCOS患者作为研究对象,予药物治疗3个月,根据治疗后是否发生内分泌代谢失调分为发生组(n=20)与未发生组(n=50)。分别于治疗前后检测患者血清IL-18、TGF-β、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平及内分泌指标[卵泡刺激素(FSH)、黄体生成素(LH)、游离睾酮(T)、雌二醇(E_(2))];比较两组基线资料及实验室指标,并分析血清IL-18/TGF-β水平与PCOS患者治疗后发生内分泌代谢失调的关系。结果治疗后,两组患者血清IL-18、TGF-β、IL-18/TGF-β、FSH、LH、T、E_(2)、TNF-α、IL-6水平均较治疗前降低(P>0.05);回归分析结果显示,血清TNF-α、IL-6、IL-18、TGF-β、IL-18/TGF-β水平过高是PCOS患者治疗后发生内分泌代谢失调的影响因素(OR>1,P<0.05)。结论PCOS患者治疗后发生内分泌代谢失调可能与血清IL-18/TGF-β水平过高有关。

Objective To investigate the relationship between serum interleukin-18(IL-18)/transforming growth factor-β(TGF-β)and endocrine and metabolic disorders in patients with polycystic ovary syndrome(PCOS).Methods 70 cases of PCOS patients admitted to the Second Affiliated Hospital of Xinjiang Medical University from April 2018 to November 2019 were selected as the research subjects.They were given drug therapy for 3 months,and were divided into the occurrence group(n=20)and the non-occurrence group(n=50)according to whether endocrine and metabolic disorders occurred after treatment.Serum levels of IL-18,TGF-β,interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and endocrine indexes[follicle stimulating hormone(FSH),luteinizing hormone(LH),free testosterone(T),estradiol(E_(2))]were detected before and after treatment,respectively.The baseline data and laboratory indicators of the two groups were compared,and the relationship between serum IL-18/TGF-β level and endocrine and metabolic disorders in PCOS patients after treatment was analyzed.Results After treatment,the serum levels of IL-18,TGF-β,IL-18/TGF-β,FSH,LH,T,E_(2),TNF-α and IL-6 in both groups were decreased compared with before treatment(P>0.05).Regression analysis showed that high levels of serum TNF-α,IL-6,IL-18,TGF-β and IL-18/TGF-βwere the influencing factors of endocrine and metabolic disorders in PCOS patients after treatment(OR>1,P<0.05).Conclusions The endocrine and metabolic disorders in PCOS patients after treatment may be related to the high levels of serum IL-18/TGF-β.